Table 1 LncRNAs that are involved in Gemcitabine (GEM) response in tumor cells
From: Role of the long non-coding RNAs in regulation of Gemcitabine response in tumor cells
Study | Year | Tumor Type | LncRNA | Target | Samples | Results | Clinical Application |
|---|---|---|---|---|---|---|---|
Gao (8) | 2021 | Non-small cell lung | MEG3 | PTEN | A549 and H520 cell lines Xenograft models | Decreased GEM resistance | Diagnosis |
Sun (29) | 2019 | Osteosarcoma | PVT1 | miR-152/c-MET | MG63 and 293 T cell lines Xenograft model | Increased GEM resistance | Diagnosis |
Hong (34) | 2020 | Colorectal | AGAP2-AS1 | miR-497/ FGFR1 | 116T 116Â N DLD-1, SW480, HT29, CaCO2, RKO, HCT8 and 293T cell lines Xenograft model | Increased GEM resistance | Diagnosis and prognosis |
Xu (37) | 2021 | Pancreatic | HIF1A-AS1 | HIF1a | 69T(24 GEM-sensitive) BxPC3 and PANC1 cell lines Xenograft model | Increased GEM resistance | Diagnosis and prognosis |
Pan (39) | 2016 | Bladder carcinoma | UCA1 | miR-196a-5p/CREB | 35T 18Â N 5637 and UMUC-2 cell lines Xenograft model | Increased GEM resistance | Diagnosis |
Xiong (46) | 2019 | Pancreatic | GSTM3TV2 | Let-7/LAT2 | 180T 180Â N AsPC-1/GR and MIAPaCa-2 cell lines Xenograft model | Increased GEM resistance | Diagnosis and Prognosis |
Xu (49) | 2021 | Pancreatic | DLEU2L | BRCA2 | PANC-1 cell line Xenograft model | Decreased GEM resistance | Diagnosis |
Liu (53) | 2019 | Pancreatic | HCP5 | miR-214-3p/HDGF | 28T 28Â N PANC-1 and SW 1990 cell lines Xenograft model | Increased GEM resistance | Diagnosis and prognosis |
Zhou (59) | 2020 | Pancreatic | PVT1 | miR-619/Pygo2 | PANC-1 and ASPC1 human cell lines Xenograft model | Increased GEM resistance | Diagnosis and prognosis |
Lu (60) | 2021 | Cholangiocarcinoma | LINC00665 | miR-424-5p/BCL9L | 100T 100Â N HuCCT1, HuH28, SNU-1196, SNU-1079, SNU-308, SNU245, SNU-478, SNU-869 and HEK293T cell lines Xenograft model | Increased GEM resistance | Diagnosis and prognosis |
Xie (61) | 2018 | Bladder | CDKN2B-AS | let-7/ CTNNB1 | 81T 34Â N SV-HUC-1, J82 and T24 cell lines | Increased GEM resistance | Diagnosis and prognosis |
Yu (66) | 2022 | Pancreatic | SNHG16 | SMAD4 | SW1990, PANC-1, ASPC-1, BxPC3 and HPDE cell lines | Increased GEM resistance | Diagnosis |
Zhuang (73) | 2017 | Bladder | LET | NF90 and miR-145 | 60T 48Â N T24, 5637, J82, SW780, BIU87, ScaBER and UMUC3 cell lines Xenograft model | Decreased GEM resistance | Diagnosis and prognosis |
Liu (75) | 2018 | Pancreatic | GAS5 | miR-221/ SOCS3 | 60T 60Â N HPDE6-C7 s PANC-1, AsPC-1, Capan-2, SW1990 and BXPC-3 cell lines Xenograft model | Decreased GEM resistance | Diagnosis and prognosis |
Chi (76) | 2021 | Pancreatic | UCA1 | SOCS3 | 35T 35Â N Human PSC, PANC-1 and HEK-293T cell lines Xenograft model | Increased GEM resistance | Diagnosis |
Shen (85) | 2020 | Cholangiocarcinoma | LINC01714 | FOXO3 | 70T 70Â N HuCCT1 and CCLP1 cell lines Xenograft model | Decreased GEM resistance | Diagnosis and prognosis |
Shi (92) | 2019 | Pancreatic | LINC00346 | miR-188-3p/ BRD4 | 24T PANC-1, MIA PaCa-2, Capan-1 and BxPC-3 cell lines Xenograft model | Increased GEM resistance | Diagnosis |
Li (94) | 2015 | Pancreatic | HOTTIP | HOXA13 | 90T PANC-1, MIA PaCa-2, Capan-2, SW1990, and BxPC-3 cell lines Xenograft model | Increased GEM resistance | Diagnosis |
Wang (96) | 2021 | Pancreatic | ANRIL | miR-181a/ HMGB1 | PANC-1, BxPC-3 and HPDE cell lines | Increased GEM resistance | Diagnosis |
Xue (124) | 2020 | Gallbladder | SSTR5-AS1 | NONO | 110T 110Â N GBC-SD, SGC-996 and NOZ cell lines Xenograft model | Increased GEM resistance | Diagnosis and prognosis |
Zhang (130) | 2019 | Pancreatic | SNHG14 | miR-101 | SW1990 cell line | Increased GEM resistance | Diagnosis |
Chen (137) | 2016 | Breast | ROR | miR-34a | MDA-MB-231 and MCF10A cell lines | Increased GEM resistance | Diagnosis |
An (138) | 2020 | Pancreatic | HOST2 | - | BxPC-3, CFPAC-1, SU.86.86, PANC-1, Hs766T and AsPC-1 cell lines | Increased GEM resistance | Diagnosis |
Sun (141) | 2019 | Pancreatic | MSC-AS1 | miR-29b-3p/ CDK14 | 45T 45Â N PANC-1 and BxPC-3 cell lines | Increased GEM resistance | Diagnosis and prognosis |
Li (142) | 2019 | Bladder | GHET1 | ABCC1 | 74T(41 GEM-sensitive) J82, T24, SV-HUC-1 J82/Gem and T24/Gem cell lines | Increased GEM resistance | Diagnosis and prognosis |
An (143) | 2018 | Bladder | FOXD2-AS1 | miR-143/ ABCC3 | T24 and 5637 cell lines Xenograft model | Increased GEM resistance | Diagnosis |
Yang (150) | 2020 | Pancreatic | SLC7A11-AS1 | NRF2 | 27T 27Â N BxPC-3, PANC-1 and AsPC-1 cell lines Xenograft model | Increased GEM resistance | Diagnosis and prognosis |
Ye (151) | 2022 | Pancreatic | DBH-AS1 | miR-3163/ USP44 | 172T 16Â N HPDE and PC cell lines Xenograft model | Decreased GEM resistance | Diagnosis and prognosis |
Hua (154) | 2019 | Pancreatic | SBF2-AS1 | miR-142-3p/ TWF1 | 82T 82Â N AsPC-1, HPAC, BxPC-3 and PANC-1 cell lines | Increased GEM resistance | Diagnosis and prognosis |
Xu (157) | 2019 | Gastric | MVIH | E-cadherin and Vimentin | Human BGC-823 cell lines | Decreased GEM resistance | Diagnosis |